Published in Health and Medicine Week, April 20th, 2006
Operating loss for the year was reduced by 20% to $27.3 million from $34 million in 2004 (excluding the $1.7 million effect of consolidating its share of Lumera's losses in 2004, the operating loss improvement was 18%) and the net loss to common shareholders was reduced by 9.6% to $30.3 million or $1.35 per share versus the 2004 equivalents of $33.5 million or $1.56 per share. The company ended the year with a revenue backlog of $3.4 million
Revenues for the fourth quarter were $2.7 million, a decrease of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health and Medicine Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.